Cancer News and Research

Latest Cancer News and Research

Glutaminase inhibitor: New potential target for brain tumors

Scientists at Johns Hopkins have identified a compound that could be used to starve cancers of their sugar-based building blocks. The compound, called a glutaminase inhibitor, has been tested on laboratory cultured, sugar-hungry brain cancer cells and, the scientists say, may have the potential to be used for many types of primary brain tumors.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.

19 Nov 2010

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting in Berlin, Germany on November 18, 2010.

19 Nov 2010

3Sbio converts US$2.58 million debenture into Isotechnika Pharma

3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced that it has recently converted the remaining US$2.58 million of a US$4.5 million debenture convertible into Isotechnika Pharma Inc. ("Isotechnika") common shares issued on August 23, 2010.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

19 Nov 2010

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.

19 Nov 2010

Scientists discover bone matrix plays a vital role in tissue hardening

Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function. The finding has immediate implications for understanding several rare hearing disorders, they said, and ultimately could offer insight into such conditions as osteoporosis, arthritis, cardiovascular disease and cancer.

19 Nov 2010

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

19 Nov 2010

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.

19 Nov 2010

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company's senior executives presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, ongoing in Berlin, Germany.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

GWCI join forces with Banca Civica to fight cancer in Washington, D.C.

The GW Cancer Institute at The George Washington University Medical Center has joined forces with Banca Civica, a financial institution from Spain pioneering the innovative concept of civic banking, to fight cancer in Washington, D.C.

19 Nov 2010

Volpara breast imaging software receives FDA clearance

Offering radiologists a reliable and cost-effective tool to generate automatic volumetric breast density values, Volpara, Ltd., announced today that it has received clearance from the U.S. Food & Drug Administration for its Volpara breast imaging software. Volpara, a subsidiary of Matakina Technology, Limited of New Zealand, is responsible for commercial operations in the United States.

19 Nov 2010

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics," held in Berlin, Germany, November 16-19.

19 Nov 2010

Women prefer diet advice from women: Study

A new study shows that women do not pay heed to diet advice from men. The study conducted by the Australian National University (ANU) suggests women are more inclined to listen and change their behaviour if the speaker is also female.

18 Nov 2010

COPD both a burden and a loss

Patients with Chronic Obstructive Pulmonary Disease, or COPD, revealed that they perceive their disease as both a burden they must deal with and as a loss they have experienced, according to recent in-home research conducted by GlaxoSmithKline. Patients participating in the research characterized their sense of loss as a combination of factors including loss of energy, loss of control, loss of independence and loss of their old self.

18 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

A Yorkshire Cancer Research scientist has earned himself a national medical award for helping pioneer life-saving surgical improvements to the way tumours are removed from colon cancer patients.

18 Nov 2010

Cancer News and Research

Latest Cancer News and Research

Glutaminase inhibitor: New potential target for brain tumors

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

3Sbio converts US$2.58 million debenture into Isotechnika Pharma

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

Scientists discover bone matrix plays a vital role in tissue hardening

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

GWCI join forces with Banca Civica to fight cancer in Washington, D.C.

Volpara breast imaging software receives FDA clearance

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

Women prefer diet advice from women: Study

COPD both a burden and a loss

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in